Albion Financial Group UT decreased its stake in Celgene Corp. (NASDAQ:CELG) by 55.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 69,181 shares of the biopharmaceutical company’s stock after selling 85,671 shares during the period. Celgene Corp. makes up approximately 1.2% of Albion Financial Group UT’s portfolio, making the stock its 24th largest position. Albion Financial Group UT’s holdings in Celgene Corp. were worth $7,231,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of CELG. Vanguard Group Inc. increased its stake in shares of Celgene Corp. by 0.8% in the second quarter. Vanguard Group Inc. now owns 47,833,717 shares of the biopharmaceutical company’s stock worth $4,717,840,000 after buying an additional 395,600 shares during the period. BlackRock Institutional Trust Company N.A. increased its stake in shares of Celgene Corp. by 0.6% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 20,241,642 shares of the biopharmaceutical company’s stock worth $1,996,433,000 after buying an additional 117,543 shares during the period. Jennison Associates LLC increased its stake in shares of Celgene Corp. by 14.1% in the third quarter. Jennison Associates LLC now owns 15,921,002 shares of the biopharmaceutical company’s stock worth $1,664,222,000 after buying an additional 1,967,645 shares during the period. BlackRock Fund Advisors increased its stake in shares of Celgene Corp. by 0.3% in the second quarter. BlackRock Fund Advisors now owns 15,066,831 shares of the biopharmaceutical company’s stock worth $1,486,042,000 after buying an additional 48,168 shares during the period. Finally, Carmignac Gestion increased its stake in shares of Celgene Corp. by 0.5% in the third quarter. Carmignac Gestion now owns 9,755,225 shares of the biopharmaceutical company’s stock worth $1,019,714,000 after buying an additional 46,866 shares during the period. 76.43% of the stock is owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Celgene Corp. (NASDAQ:CELG)

Shares of Celgene Corp. (NASDAQ:CELG) traded down 0.63% during trading on Monday, reaching $120.30. 3,297,789 shares of the company were exchanged. The company has a market capitalization of $93.26 billion, a PE ratio of 45.69 and a beta of 1.71. The firm’s 50 day moving average price is $108.41 and its 200 day moving average price is $106.51. Celgene Corp. has a one year low of $93.05 and a one year high of $127.00.

Celgene Corp. (NASDAQ:CELG) last released its earnings results on Thursday, October 27th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.48 by $0.10. The firm earned $2.98 billion during the quarter, compared to analyst estimates of $2.84 billion. Celgene Corp. had a return on equity of 70.48% and a net margin of 19.71%. Celgene Corp.’s revenue was up 27.8% compared to the same quarter last year. During the same period last year, the business posted $1.23 earnings per share. Equities research analysts forecast that Celgene Corp. will post $5.92 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Celgene Corp. (CELG) Stake Decreased by Albion Financial Group UT” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States and international trademark and copyright laws. The original version of this piece can be accessed at https://www.thecerbatgem.com/2016/11/28/celgene-corp-celg-stake-decreased-by-albion-financial-group-ut.html.

A number of equities analysts have recently commented on CELG shares. Vetr downgraded shares of Celgene Corp. from a “strong-buy” rating to a “buy” rating and set a $115.50 price objective for the company. in a report on Monday, October 31st. BTIG Research reaffirmed a “buy” rating and set a $138.00 price objective on shares of Celgene Corp. in a report on Sunday, August 21st. BMO Capital Markets reaffirmed an “outperform” rating and set a $141.00 price objective on shares of Celgene Corp. in a report on Monday, October 3rd. JPMorgan Chase & Co. reaffirmed an “overweight” rating and set a $136.00 price objective on shares of Celgene Corp. in a report on Friday, August 19th. Finally, Jefferies Group reaffirmed a “buy” rating and set a $134.00 price objective on shares of Celgene Corp. in a report on Monday, October 17th. Five investment analysts have rated the stock with a hold rating and twenty-five have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $136.34.

In other Celgene Corp. news, major shareholder Corp /De/ Celgene purchased 800,150 shares of the business’s stock in a transaction on Monday, October 24th. The shares were bought at an average cost of $14.00 per share, for a total transaction of $11,202,100.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Michael A. Friedman sold 18,600 shares of the firm’s stock in a transaction on Wednesday, November 9th. The shares were sold at an average price of $116.10, for a total value of $2,159,460.00. Following the completion of the sale, the director now owns 18,600 shares in the company, valued at $2,159,460. The disclosure for this sale can be found here. 0.97% of the stock is owned by corporate insiders.

Celgene Corp. Company Profile

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

5 Day Chart for NASDAQ:CELG

Receive News & Stock Ratings for Celgene Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corp. and related stocks with our FREE daily email newsletter.